GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Patrys PAB.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.02

—

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Patrys — daily ASX:PAB

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Patrys on TradingView ↗
Market value
A$3.9m
Last close × shares
Volume
1.1m
Shares, 9 Nov 2026

About Patrys

Its shares trade on ASX under the ticker PAB.AX. It has been listed since 13 July 2007. In the fiscal year to 30 June 2026, it reported revenue of A$8,985 and a net loss of A$3.4m. At that date it held total assets of A$11.1m and shareholders' equity of A$10.2m.

Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm is engaged in conducting research and development activities in the biopharmaceutical sector. The firm's products include PAT-SM6, PAT-LM1 and PAT-SC1. PAT-SM6 is a natural human antibody that binds to multiple types of cancer, including solid tumors, such as melanoma, breast, colon and pancreatic, as well as blood-based cancers, such as multiple myeloma. PAT-SM6 has completed its Phase I clinical trials for melanoma and Phase I/IIa clinical trials for multiple myeloma. PAT-LM1 is a natural human antibody that can be used for treatment of multiple types of cancer, with potency against colon, lung, breast, ovary and pancreatic cancers. PAT-LM1 is in pre-clinical stage of its study. The company offers 3E10 Deoxymab, a lupus autoantibody. The company is toxic to cancer cell that has deficiencies in deoxyribonucleic acid repair.

Figures and description from our data supplier, not checked against the company's own report.

More about Patrys →

Latest on Patrys

Our reporting

We have not reported on Patrys yet.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Patrys's ticker?

Patrys trades as PAB.AX on ASX, under ISIN AU000000PAB9.

What was Patrys's last closing price?

0.02 on 9 Nov 2026. The figure is in AUD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.